Keyphrases
Acetylcholine Receptor (AChR)
18%
Acetylcholine Receptor Antibody
100%
Activities of Daily Living Scale
45%
Confidence Interval
18%
Eculizumab
100%
Long-term Tolerability
9%
MG-QOL15
45%
Minimal Symptom Expression
100%
Myasthenia Gravis
100%
Open-label Extension
27%
Patient-reported Outcomes
9%
Patient-Reported Outcomes Measurement Information System (PROMIS)
9%
Placebo
27%
Quality of Life Questionnaire
9%
Randomized Double-blind Placebo-controlled Study
9%
Therapy Efficacy
9%
Tolerability
9%
Trial Registration
9%
Medicine and Dentistry
Activity of Daily Living Scale
45%
Cholinergic Receptor Antibody
100%
Eculizumab
100%
Mental Capacity
9%
Myasthenia gravis
100%
Patient-Reported Outcome
18%
Placebo
27%
Placebo-Controlled Study
9%
Quality of Life
9%
Pharmacology, Toxicology and Pharmaceutical Science
Cholinergic Receptor Antibody
100%
Eculizumab
100%
Myasthenia gravis
100%
Placebo
27%
Placebo-Controlled Study
9%
Tolerability
18%
Neuroscience
Cholinergic Receptor Antibody
100%
Eculizumab
100%
Myasthenia gravis
100%
Placebo
36%